1. Home
  2. EIC vs LUNG Comparison

EIC vs LUNG Comparison

Compare EIC & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • EIC
  • LUNG
  • Stock Information
  • Founded
  • EIC N/A
  • LUNG 1995
  • Country
  • EIC United States
  • LUNG United States
  • Employees
  • EIC N/A
  • LUNG N/A
  • Industry
  • EIC Finance/Investors Services
  • LUNG Industrial Specialties
  • Sector
  • EIC Finance
  • LUNG Health Care
  • Exchange
  • EIC Nasdaq
  • LUNG Nasdaq
  • Market Cap
  • EIC 242.6M
  • LUNG 248.0M
  • IPO Year
  • EIC 2019
  • LUNG 2020
  • Fundamental
  • Price
  • EIC $16.42
  • LUNG $7.30
  • Analyst Decision
  • EIC
  • LUNG Strong Buy
  • Analyst Count
  • EIC 0
  • LUNG 7
  • Target Price
  • EIC N/A
  • LUNG $13.71
  • AVG Volume (30 Days)
  • EIC 116.0K
  • LUNG 237.6K
  • Earning Date
  • EIC 11-14-2023
  • LUNG 10-28-2024
  • Dividend Yield
  • EIC 13.63%
  • LUNG N/A
  • EPS Growth
  • EIC N/A
  • LUNG N/A
  • EPS
  • EIC 0.80
  • LUNG N/A
  • Revenue
  • EIC N/A
  • LUNG $76,583,000.00
  • Revenue This Year
  • EIC N/A
  • LUNG $22.73
  • Revenue Next Year
  • EIC N/A
  • LUNG $19.02
  • P/E Ratio
  • EIC $20.31
  • LUNG N/A
  • Revenue Growth
  • EIC N/A
  • LUNG 26.26
  • 52 Week Low
  • EIC $13.00
  • LUNG $5.46
  • 52 Week High
  • EIC $16.48
  • LUNG $14.84
  • Technical
  • Relative Strength Index (RSI)
  • EIC 73.63
  • LUNG 41.60
  • Support Level
  • EIC $15.83
  • LUNG $7.18
  • Resistance Level
  • EIC $15.97
  • LUNG $8.59
  • Average True Range (ATR)
  • EIC 0.18
  • LUNG 0.40
  • MACD
  • EIC 0.07
  • LUNG -0.16
  • Stochastic Oscillator
  • EIC 98.11
  • LUNG 7.74

About EIC Eagle Point Income Company Inc.

Eagle Point Income Co Inc is a closed-end management investment company. Its primary investment objective is to generate high current income, with a secondary objective to generate capital appreciation.

About LUNG Pulmonx Corporation

Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.

Share on Social Networks: